GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (STU:CXF) » Definitions » 14-Day RSI

Chimerix (STU:CXF) 14-Day RSI : 62.60 (As of Mar. 03, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Chimerix 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2025-03-03), Chimerix's 14-Day RSI is 62.60.

The industry rank for Chimerix's 14-Day RSI or its related term are showing as below:

STU:CXF's 14-Day RSI is ranked worse than
90.39% of 1520 companies
in the Biotechnology industry
Industry Median: 43.92 vs STU:CXF: 62.60

Competitive Comparison of Chimerix's 14-Day RSI

For the Biotechnology subindustry, Chimerix's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chimerix's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimerix's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Chimerix's 14-Day RSI falls into.



Chimerix  (STU:CXF) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chimerix  (STU:CXF) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Chimerix 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Chimerix's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Chimerix Business Description

Traded in Other Exchanges
Address
2505 Meridian Parkway, Suite 100, Durham, NC, USA, 27713
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.

Chimerix Headlines

No Headlines